Zahra Kashi, Shiva Borzouei, Ozra Akhi, Narges Moslemi Zadeh, Hamidreza Zakeri, Reza Mohammadpour Tahmtan, Rafat Bonafti, Leila Shahbazadeh,
Volume 6, Issue 1 (19 2006)
Abstract
Background: Detecting mothers with gestational diabetes mellitus (GDM) is not only important in prevention of prenatal morbidities but also has significant effect on neonatal and maternal long term outcomes. Today, there are screening tests for GDM but they are time-consuming and expensive, therefore it seems necessary to perform testes that are uses expensive but with higher sensitivity and specificity. The aim of this study was to determine a cut - off point of fasting plasma glucose (FPG) for screening of GDM.
Methods: 200 pregnant women referring to the perinatal clinic of Imam Khomeini hospital, (Sari – Iran) were studied. All cases with age ≥25 years old, history of recurrent abortion, GDM, preeclampsia, macrosomia, still birth, diabetes mellitus(DM) in first degree family or pre gestational body mass index ≥25kg/m2 were selected. Those with pre gestational diabetes mellitus were excluded. All of participants underwent a 50 g glucose challenge test (GCT) between the 24th and 28th gestational week. If 1- hour plasma glucose was more than 130 mg/dl, a 3- hour 100g oral glucose tolerance test (OGTT) was performed. The diagnosis of GDM was made by ADA 2006 recommendation (Carpenter and Coustan diagnostic criteria). Referring to the Receiver Operative Characteristic Curve, level of FPG having highest sensitivity and specificity in diagnosis of GDM was determined.
Results: From 200 participants, 65 women had positive GCT, of them 58 (response rate 89%) referred for 100g OGTT and 20(10%) were diagnosed GDM. Using ROC curve and under curve area of 0.853 the FBG level of 91.5 mg/dl, showed the highest sensitivity and specificity, 80% and 92% respectively in diagnosis of GDM.
Conclusion: FBG ≥ 91.5 mg/dl has good sensitivity and specificity in screening of GDM. Since this is simpler and cheaper than 50g GCT, is recommended as a screening method in diagnosis of GDM.
Nadiyeh Mohammadpour, Zaher Etemad, Khalid Mohammadzade, Asieh Abbassi Daloii,
Volume 20, Issue 3 (2-2021)
Abstract
Background: The hepatokines are now considered potential targets for the treatment of type 2 diabetes disorders. The aim of this study was to investigate the effect of 12 weeks combined training with Canagliflozin on some hepatokines in type 2 diabetic men.
Methods: In this quasi-experimental study, 44 men with type 2 diabetes (Mean age 33.2 ± 4.5 years, body mass index 27.3±3.0) from Tehran city in 2019 were randomly divided into four groups (n=11) of control, drug, exercise and exercise-drug groups. Combined training was performed 3 sessions per week, 45 minutes for 12 weeks. Subjects were given 200 mg of canagliflozin for 12 weeks. Blood samples and anthropometric characteristics were obtained before and 24 hours after the intervention at 12-hour fasting. Data were analyzed using two-way ANOVA with repeated measures, t-test and Bonferroni post hoc test at P<0.05.
Results: The results showed that 12 weeks of exercise with Canagliflozin intervention significantly reduced angiopoietin-3 and angiopoietin-4, FGF-21 and HFREP-1 levels in type 2 diabetic men (P=0.001). Also, after the intervention of exercise with Canagliflozin, levels of angiopoietin-3, angiopoietin-4, FGF-21, and HFREP-1 were significantly lower than the pre-test (P<0.001).
Conclusion: According to the results of research, it is possible that intervention of exercise with Canagliflozin can help treat of disorders due to type 2 diabetes by reducing hepatokines.
